TABLE 2.

Results of testing GMS 284756 and 16 other orally administered agents against 198 strains of H. influenzae isolated from Latin American laboratories participating in the SENTRY Antimicrobial Surveillance Program, 1999

Antimicrobial agent	MIC (μg/ml)			% Susceptiblea
	50%	90%	Range
BMS 284756	≤0.03	≤0.03	≤0.03–0.06	100.0 (≤4)
Ciprofloxacin	≤0.015	≤0.015	≤0.015–0.003	100.0
Gatifloxacin	≤0.015	≤0.015	≤0.015–0.03	100.0
Levofloxacin	≤0.03	≤0.03	≤0.03–0.06	100.0
Trovafloxacin	≤0.03	≤0.03	≤0.03	100.0
Ampicillinb	≤0.5	>4	≤0.5–>4	85.4
Amoxicillin-clavulanate	0.5	1	≤0.25–2	100.0
Cefaclor	2	8	≤0.25–32	97.0
Cefuroxime	1	2	≤0.06–4	100.0
Cefixime	≤0.03	0.06	≤0.03–0.25	100.0
Cefpodoxime	0.06	0.12	≤0.03–0.25	100.0
Azithromycin	0.5	1	≤0.12–2	100.0
Clarithromycin	4	8	≤0.25–16	97.5
Chloramphenicol	≤2	≤2	≤2–16	99.0
Tetracycline	≤2	≤2	≤2–16	99.0
Trimethoprim-sulfamethoxazole	≤0.5	>4	≤0.5–>4	62.0
Rifampin	≤1	≤1	≤1	100.0

^aSusceptibility criteria of the NCCLS (5, 6). Where interpretive criteria do not exist, the criteria in parentheses were applied for comparison purposes only. 

^bA total of 15.2% of strains produced a β-lactamase (detected by the chromogenic cephalosporin method).